drugset
drugset / Trial / NCT07625306

Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

NCT07625306 ↗

Phase 3 Not yet recruiting 240 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).

Timeline

Start
2026-08-31
Primary completion
2028-12-07
Completion
2028-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pelacarsen Antisense oligonucleotide 80 mg Subcutaneous

Indications

acute coronary syndrome